RBDCOV project members met at Vall d’Hebron this week to move forward in the development of the BIMERVAX® vaccine. RBDCOV is an EU-funded project that aims to test the HIPRA vaccine against COVID-19 in children (including adolescents) and immunocompromised individuals. The meeting provided a chance to outline the forthcoming steps in the research of the vaccine and to update on the provisional results of the study in immunocompromised adults, confirming its safety and efficacy.
Asphalion is proud regulatory partner of RBDCOV by carrying out the regulatory pathway throughout the whole project by seeking scientific advice for the RBDCOV clinical trials with the European regulatory authorities, preparing the required documents to support clinical trial applications and supporting the preparation of the eCTD registration dossier currently under rolling review, among other regulatory activities.
For more details about the project, have a look at the project´s website: RBDCOV Project Website
For further information, you can contact us at: email@example.com